BETTA PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.54 CNY | +3.66% |
|
+12.49% | -21.36% |
ETFs positioned on Betta Pharmaceuticals Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 2 M€ | -16.59% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 2,808 M€ | +5.90% | - | |
| 0.00% | 441 M€ | +4.60% | - | |
| 0.00% | 149 M€ | +2.17% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 15 M€ | +11.24% |
Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
40.54
CNY
Average target price
54.14
CNY
Spread / Average Target
+33.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.36% | 2.34B | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- 300558 Stock
- Funds and ETFs Betta Pharmaceuticals Co., Ltd.
